Search company, investor...
Search
Biose Industrie company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

biose.com

Founded Year

1951

Stage

Private Equity | Alive

Total Raised

$34M

Last Raised

$34M | 2 yrs ago

About Biose Industrie

Biose Industrie provides a full range of services as a CDMO for Live biotherapeutic products (LPB).

Biose Industrie Headquarters Location

24 Avenue Georges Pompidou

Aurillac, 15000,

France

+33 4 71 46 80 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Biose Industrie

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biose Industrie is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Biose Industrie Patents

Biose Industrie has filed 2 patents.

The 3 most popular patent topics include:

  • Lactobacillaceae
  • Bacterial vaginosis
  • Bacteriology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/1/2017

12/14/2021

Lactobacillaceae, Bacteriology, Bacterial vaginosis, Microbiology, Microbiomes

Grant

Application Date

3/1/2017

Grant Date

12/14/2021

Title

Related Topics

Lactobacillaceae, Bacteriology, Bacterial vaginosis, Microbiology, Microbiomes

Status

Grant

Latest Biose Industrie News

EverImmune engages Biose Industrie to manufacture its leading oncology-related Live Biotherapeutic

Dec 13, 2021

EverImmune engages Biose Industrie to manufacture its leading oncology-related Live Biotherapeutic Microbiome oncology company turns to world-leading CDMO to handle the challenges of manufacturing and scale-up Microbiome-focused oncology drug company everImmune , a spin-out from France’s top cancer research center, has signed an agreement with contract development and manufacturing organization (CDMO) Biose Industrie to manufacture the drug substance and finished drug product for its leading live biotherapeutic product (LBP) candidate. The orally-administered drug candidate, called Oncobax® AK, consists of a proprietary strain of Akkermansia. It has been shown in preclinical work to enhance patient responses to immunotherapy drugs in both non-small cell lung cancer and renal cell carcinoma. The product works by modulating the gut microbiota of anticancer immunotherapy non-responders and turning them into responders. As a strict anaerobe with particular requirements for growth, Akkermansia is notoriously difficult to deliver as a drug. Jean Luc Marsat, Chairman of everImmune, says, “In choosing our partners to support our clinical trial, we have encouraged players in the French ecosystem. Biose then became obvious to us as a CDMO service provider to develop our Akkermansia -based product Oncobax® AK and we are fully satisfied with the partnership. Being able to bring our LBP candidate to cancer patients depends entirely on whether it can be manufactured according to drug standards. Biose Industrie was the clear choice to produce our strain of Akkermansia.” Biose Industrie has worked extensively on the strain and is able to produce the lyophilized product at higher concentrations than anyone else has achieved in the industry, allowing the dose to be packaged in smaller formats. Together everImmune and the CDMO have completed the process development and are now working on GMP manufacturing. Biose Industrie CEO Adrien Nivoliez says, “We are really proud to support everImmune on this journey. The fact we can help develop the cutting-edge microbiome science on responder/non-responder populations coming out of Laurence Zitvogel’s lab is a clear indication that Biose Industrie is successfully teaming up with leaders in the microbiome world. We look forward to continued success with Jean Luc Romain and the team at everImmune.” The first clinical trial using Oncobax® AM is expected to begin recruiting for April 2022. About Biose Industrie Biose Industrie is a world leading CDMO for Live Biotherapeutic Products. Founded in 1951 by pharmacists and microbiologists, Biose Industrie has more than 60 years of experience in the development and production of live bacteria-based drugs. The company offers lab development specialised in microbiology and is Drug GMP certified for the manufacturing of API, clinical batches and commercial products. About everImmune everImmune is a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology. It harnesses the gut microbiota for the development of a unique theragnostic approach to restoring the response of immune-checkpoint inhibitors (ICIs) in cancer patients. Created in 2016 by co-founders Pr. Laurence Zitvogel and Dr. Romain Daillere, everImmune is a spinoff from Gustave Roussy; Europe’s first cancer institute, based in Paris, France. The company is part of ONCOBIOME, the first European program dedicated to microbiome and cancer, funded by the European Union. Sign Up to Free Newsletter The Microbiome Drug Database

Biose Industrie Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biose Industrie Rank

  • When was Biose Industrie founded?

    Biose Industrie was founded in 1951.

  • Where is Biose Industrie's headquarters?

    Biose Industrie's headquarters is located at 24 Avenue Georges Pompidou, Aurillac.

  • What is Biose Industrie's latest funding round?

    Biose Industrie's latest funding round is Private Equity.

  • How much did Biose Industrie raise?

    Biose Industrie raised a total of $34M.

  • Who are the investors of Biose Industrie?

    Investors of Biose Industrie include Cathay Capital Private Equity.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.